Codexis Stock Today

Stock Highlights

Codexis (CDXS) is listed on NASDAQ Exchange in USA. Codexis operates within the Life Sciences Tools & Services industry. The company conducts business in the Life Sciences Tools & Services sector. Codexis market capitalization is 159.02 M, placing the company in the small-cap tier across life sciences tools & services. To frame that market cap reading, note enterprise value near 140.39 M, about 90.87 M shares outstanding, and a workforce of about 146 people. The company has 10.77 M shares sold short (2.53 days to cover). The gap between operating margin (35.89%) and net margin (-62.47%) suggests significant non-operating costs such as interest or taxes. The company reported previous year's revenue of 70.39 M. Net Loss for the year was -43.97 M with profit before overhead, payroll, taxes, and interest of 8.74 M. Codexis financial stability analysis Ownership Allocation The majority of Codexis' outstanding shares are owned by institutional holders. Institutional investors such as pension funds, mutual funds, and asset managers typically hold large positions as part of their investment mandates, managing money on behalf of clients or beneficiaries. As a result, they are subject to reporting requirements and oversight rules - such as 13F filings and position disclosure thresholds - that do not apply to individual retail investors. Codexis has approximately 73% of its outstanding shares held by institutional investors, 8% by insiders, and 20% in public hands. Check Codexis Ownership Details

Codexis Hype to Price Pattern

Open Interest Against 2026-06-18 Codexis Option Contracts

Current option-chain data for Codexis covers the June 18, 2026 expiration. The chain lists 14 contracts (7 calls, 7 puts). Key chain metrics currently indicate implied volatility near 2.01 and put/call open-interest ratio around 0.06. Strike-level open interest is available in the full chain. View more details.

Notable Updates

CEO President	Stephen MBBS
CEO and President and Director	John Nicols
Business Concentration	Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Nasdaq Industrial, NASDAQ Composite, NASDAQ Composite Total, Health Care, Life Sciences Tools & Services, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation 7 Opinions
Financial Strength Codexis posted a Gross Profit Margin of 60.0%, an Operating Margin of 35.9%, and a Return On Assets of -31.0% for the reported period. Codexis shows pressured financial positioning across liquidity, leverage, and earnings quality. The earnings picture reflects near-term margin compression relative to deployed assets. Current Value Last Year Change From Last Year  10 Year Trend Asset Turnover 0.72 0.4762 Way Up Slightly volatile Gross Profit Margin 0.6 0.7949 Way Down Very volatile Total Current Liabilities 28.2 M 25.3 M Moderately Up Slightly volatile Non Current Liabilities Total 75.5 M 72 M Sufficiently Up Slightly volatile Total Assets 128 M 147.8 M Fairly Down Slightly volatile Total Current Assets 89.7 M 96.8 M Significantly Down Slightly volatile
Debt Levels Codexis posted -$0.78 in Net Debt To EBITDA, a Debt To Equity of 1.52x, and $42.1 million in Long Term Debt for the reported period. Additional disclosures note a Long Term Debt To Capitalization of 46.0% and $52 thousand in Long Term Debt Total, relevant to Codexis's position within the Health Care sector. Current Assets Codexis posted $0.02 in Intangibles To Total Assets, $128.0 million in Total Assets, and a Return On Assets of -31.0% for the reported period. Additional disclosures note a Debt To Assets of 52.0%, relevant to Codexis's position within the Health Care sector.

Earnings per Share Projection vs Actual

Top Institutional Holders

Institutional Holdings refers to the ownership stake in Codexis held by large financial organizations. These institutions can acquire significant blocks of Codexis' shares and often influence management decisions.

Codexis Historical Income Statement

Total Revenue is showing structural movement consistent with an increasing trend. A year ago, Total Revenue was sitting at 70.39 Million. As of now, The current year's Research Development is projected to rise to approximately 46.4 M, while Interest Expense is moving lower toward slightly above 3.2 M. View More Fundamentals

Codexis Against Markets